PATENT CLAIM ANALYSIS

Application Number: 16027988
Application Type: Utility
Filing Date: 2018-07
Publication Date: 2019-01
Patent Classification: ["514", "315000"]

Abstract:
To provide a pharmaceutical, in particular a compound which can be used as a therapeutic agent for irritable bowel syndrome (IBS). It was found that a tetrahydroisoquinolin-1-one derivative having an amide group at the 4-position or a pharmaceutically acceptable salt thereof has an excellent bombesin 2 (BB2) receptor antagonistic action. It is also found that the tetrahydroisoquinolin-1-one derivative is highly effective on bowel movement disorders. From the above, the tetrahydroisoquinolin-1-one derivative of the present invention is useful as a therapeutic agent for diseases associated with a BB2 receptor, in particular IBS.

Claim (Index 17):
The compound of  claim 16 , wherein R 4  is \u2014N(R 0 )-lower alkylene-(aryl or heteroaryl, which may each be substituted), or \u2014N(R 0 )\u2014O-lower alkylene-(aryl or heteroaryl, which may each be substituted).

Metadata:
- Claim Count in Document: 10.0
- Percentile: 95.0
- Lexical Diversity: 1.56923
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['13942158', '15350427', '12600894', '14836228', '12693597']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8031215642374414
- 35 USC 102 Novelty (BERT): 0.6023051020672457
- Combined Prediction Score: 0.7830399180204218
- Mean Citation Score: 450.04597200000006
- Max Citation Score: 550.0178
- Similarity Product: 439.96575958926667

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test